Health data firm Sophia Genetics raises $77M to support U.S. expansion

Medicine Money
Sophia Genetics estimates its AI platform is currently used by more than 850 hospitals and in the diagnosis of over 300,000 patients. (Getty/utah778)

Swiss big data startup Sophia Genetics has raised $77 million in new venture capital to help fund its expansion to its new U.S. location and bring on more staff.

The series E round was led by Generation Investment Management, a sustainable investment management firm co-founded and chaired by former Vice President Al Gore, with participation from Idinvest Partners and Sophia’s previous backers Balderton Capital and Alychlo.

The new money, which brings the Lausanne, Switzerland-based company’s fundraising total up to $140 million, will also be used to help push its artificial intelligence-based platform into new hospital systems.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Sophia Genetics’ analysis platform aims to digest genomic and radiomic data to assist in the diagnosis of patients with cancer and hereditary disorders. The company said its Sophia AI program is currently employed by more than 850 hospitals in 77 countries and has been used in the diagnosis of over 300,000 patients.

“Generation are delighted to partner with Sophia Genetics,” said Lilly Wollman, co-head of Generation’s growth equity team, in a statement. “We believe that leveraging genetic sequencing and advanced digital analysis will enable a more sustainable healthcare system.”

Last September, in announcing its new headquarters in Boston, Sophia Genetics founder and CEO Jurgi Camblong said the company had about 20 employees in the country, with plans to grow to at least 50 over the next year, as it continues supporting at least 100 university hospitals in the U.S.

Suggested Articles

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any safety alarms.

Kite hopes to win approval for KTE-X19 in mantle cell lymphoma on the strength of midphase results linking it to a 67% complete response rate.